Skip to main content

Table 1 Clinical and demographic characteristics

From: Tubular reabsorption and local production of urine hepcidin-25

Variable Controls (n = 24) Renal disease (n = 30) CABG 1–2 hours (n = 8) CABG 12–24 hours (n = 13)
Male (%) 46 80 88 85
Age (years) 39 ± 12 43 ± 24 65 ± 8 66 ± 10
Serum albumin (g/l) n.a. 34 (24–35) n.a. n.a.
Serum creatinine (μmol/l) 75 (68–83) 107 (23–147) 93 (74–116) 85 (51–102)
eGFR (ml/min/1.73 m 2 ) 84 (77–108) 57 (34–65) 73 (58–95) 85 (17–128)
Proteinuria (g/d) n.a. 4.5 (1.7-9.4) n.a. n.a.
Serum β 2 m (mg/l) n.a. 2.9 (2.2-4.6) 2.1 (1.6-2.9) 1.8 (1.3-2.5)
Serum hepcidin-25 (nmol/l) 4.4 (3.2-5.8) 3.1 (1.1-5.7) 4.7 (1.5-7.1) 14.1 (11.1-17.8)
Urine β 2 m (nmol/mmol creatinine) n.a. 142 (13–863) 312 (1528–5239) 66 (21–86)
Urine hepcidin-25 (nmol/mmol creatinine) 0.9 (0.4-1.7) 1.4 (0.3-7.1) 10.4 (0.8-18.7) 52.2 (34.0-112.1)
FE of β 2 m (%) n.a. 5.1 (0.7-39.1) 14.1 (7.1-20.7) 2.7 (0.8-3.7)
FE of hepcidin-25 (%) 1.9 (1.0-3.2) 8.0 (1.9-20.3) 21.1 (7.2-23.1) 33.1 (22.2-52.9)
Duration of CPB (min) - - 101 (63–147)# 106 (92–125)#
  1. Median (interquartile range), mean ± SD, eGFR = estimated glomerular filtration rate, n.a. = not available, FE = fractional excretion, CABG = coronary artery bypass grafting, CPB = cardiopulmonary bypass, # one patient underwent off-pump CABG.